# Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)

> **NCT04562766** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Principia Biopharma, a Sanofi Company** · enrollment: 232 (actual)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Rilzabrutinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04562766
- **Lead sponsor:** Principia Biopharma, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-14
- **Primary completion:** 2025-01-15
- **Final completion:** 2026-08-26
- **Target enrollment:** 232 (ACTUAL)
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04562766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04562766, "Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04562766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*